Literature DB >> 22419752

Cost-effectiveness analysis of amino acid PET-guided surgery for supratentorial high-grade gliomas.

Alexander Heinzel1, Stephanie Stock, Karl-Josef Langen, Dirk Müller.   

Abstract

UNLABELLED: High-grade gliomas are brain tumors associated with a devastating prognosis. Recent studies have indicated that the combined use of amino acid PET and MRI is superior to MRI alone to plan the surgical resection of high-grade gliomas. The aim of the study was to analyze the cost-effectiveness of the use of amino acid PET for the surgical resection of high-grade gliomas, compared with MRI alone, from the perspective of the national health insurance in Germany.
METHODS: A decision-tree model was set up to compare 2 strategies: the use of MRI alone and the combined use of MRI and PET for surgical resection of high-grade gliomas. For the analysis, 2 scenarios were calculated: a baseline scenario and a more expensive scenario, accounting for disease severity. To test the robustness of the results, probabilistic sensitivity analyses using Monte Carlo simulation were calculated.
RESULTS: Compared with MRI alone, the combined use of MRI and PET showed an incremental cost-effectiveness ratio of €2,948 (€1 ~ U.S.$1.3)per life-year gained for the baseline scenario and an incremental cost-effectiveness ratio of €4,105 per life-year gained for the admissible-charge-rate scenario. In the probabilistic sensitivity analysis in about 60% of the iterations, the combined use of PET and MRI was superior to MRI alone when assuming a willingness-to-pay threshold of €30,000.
CONCLUSION: The model indicates that the combined use of MRI and PET may be cost-effective. The results of this analysis have to be considered carefully because there was only limited empiric evidence for several input parameters.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22419752     DOI: 10.2967/jnumed.111.097352

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  10 in total

1.  Cost-effectiveness of (99m)Tc-MIBI in the evaluation of thyroid nodules for malignancy: a new lease of life for an old radiopharmaceutical?

Authors:  Frederik A Verburg; Florian F Behrendt; Felix M Mottaghy; Alexander Heinzel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-10-11       Impact factor: 9.236

2.  Cost-effectiveness of Fluorine-18-Fluorodeoxyglucose positron emission tomography in tumours other than lung cancer: A systematic review.

Authors:  Salvatore Annunziata; Carmelo Caldarella; Giorgio Treglia
Journal:  World J Radiol       Date:  2014-03-28

3.  Thyroid nodules with indeterminate cytology: molecular imaging with ⁹⁹mTc-methoxyisobutylisonitrile (MIBI) is more cost-effective than the Afirma gene expression classifier.

Authors:  Alexander Heinzel; Dirk Müller; Florian F Behrendt; Luca Giovanella; Felix M Mottaghy; Frederik A Verburg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-04-05       Impact factor: 9.236

Review 4.  Paediatric gliomas: diagnosis, molecular biology and management.

Authors:  Alexandros Blionas; Dimitrios Giakoumettis; Alexia Klonou; Eleftherios Neromyliotis; Ploutarchos Karydakis; Marios S Themistocleous
Journal:  Ann Transl Med       Date:  2018-06

5.  PET imaging in patients with brain metastasis-report of the RANO/PET group.

Authors:  Norbert Galldiks; Karl-Josef Langen; Nathalie L Albert; Marc Chamberlain; Riccardo Soffietti; Michelle M Kim; Ian Law; Emilie Le Rhun; Susan Chang; Julian Schwarting; Stephanie E Combs; Matthias Preusser; Peter Forsyth; Whitney Pope; Michael Weller; Jörg C Tonn
Journal:  Neuro Oncol       Date:  2019-05-06       Impact factor: 12.300

6.  Cost-effectiveness analysis of FET PET-guided target selection for the diagnosis of gliomas.

Authors:  Alexander Heinzel; Stephanie Stock; Karl-Josef Langen; Dirk Müller
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-03-15       Impact factor: 9.236

7.  Multimodal imaging-defined subregions in newly diagnosed glioblastoma: impact on overall survival.

Authors:  Flóra John; Edit Bosnyák; Natasha L Robinette; Alit J Amit-Yousif; Geoffrey R Barger; Keval D Shah; Sharon K Michelhaugh; Neil V Klinger; Sandeep Mittal; Csaba Juhász
Journal:  Neuro Oncol       Date:  2019-02-14       Impact factor: 12.300

Review 8.  State-of-the-art imaging for glioma surgery.

Authors:  Niels Verburg; Philip C de Witt Hamer
Journal:  Neurosurg Rev       Date:  2020-06-30       Impact factor: 3.042

9.  Large tumour volume reduction of IDH-mutated anaplastic glioma involving the insular region following radiotherapy.

Authors:  Gabrielle Metz; Dasantha Jayamanne; Helen Wheeler; Matthew Wong; Raymond Cook; Nicholas Little; Jonathon Parkinson; Marina Kastelan; Chris Brown; Michael Back
Journal:  BMC Neurol       Date:  2022-01-13       Impact factor: 2.474

Review 10.  Diagnostic Performance and Prognostic Value of PET/CT with Different Tracers for Brain Tumors: A Systematic Review of Published Meta-Analyses.

Authors:  Giorgio Treglia; Barbara Muoio; Gianluca Trevisi; Maria Vittoria Mattoli; Domenico Albano; Francesco Bertagna; Luca Giovanella
Journal:  Int J Mol Sci       Date:  2019-09-20       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.